Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The Pretreatment Absolute Lymphocyte Count (ALC), but Not the Absolute Monocyte Count (AMC) or ALC/AMC Ratio, Is an Independent Prognostic Factor in Aggressive Non-Hodgkin Lymphoma (aNHL)

Noridza Rivera-Rodriguez, MD, Fernando Cabanillas, MD, Carlos Montalban, Jose Francisco Tomas, MD, María José Terol, MD, PhD, Armando López-Guillermo, MD, Wandaly I. Pardo, MD, Orestes A. Pavia, MD, Margarita Bruno, MD, Karen Janice Santiago, Pablo Guisado-Vasco, MD, PhD, Angel Ruedas, MD, Raquel de Oña, Silvia Solorzano, Ana Isabel Teruel, MD, Laura Garcia-Sanchis, Jordina Rovira, MD, Ivan Dlouhy

Blood (2012) 120 (21): 1596.

https://doi.org/10.1182/blood.V120.21.1596.1596

Published: 2012

Journal Articles

Personalized Treatment with low doses of Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma in frail or Elderly Patients

Angel Ruedas, MD, Pablo Guisado, MD, PhD, Beatriz Aguado, MD, PhD, Ricardo Perez, MD, Joaquin Martinez, MD, J Valentin Garcia-Gutierrez, MD, PhD, M. Jesús Blanchard, MD, Pilar Bravo, MD, Carlos Montalban

Blood (2012) 120 (21): 5049.

https://doi.org/10.1182/blood.V120.21.5049.5049

Published: 2012

Journal Articles

Stratification Approach for Splenic Marginal Zone Lymphoma Based on Hemoglobin, Platelet Count, High LDH and Extrahilar Lymphadenopathy: The HPLL/ABC System

Carlos Montalban, MD, PhD, Victor Abraira, PhD, Luca Arcaini, Eva Domingo-Domenech, MD, Pablo Guisado-Vasco, MD, PhD, Emilio Iannitto, MD, Manuela Mollejo, MD, Estella Matutes, Andrés JM Ferreri, MD, Antonio Salar, MD, PhD, Andrea Carpaneto, MD, Ricardo Pérez, MD, Jose Luis Bello, Miguel Hernandez, Dolores Caballero, MD, Miguel A. Piris, MD, PhD

Blood (2011) 118 (21): 1583.

https://doi.org/10.1182/blood.V118.21.1583.1583

Published: 2011

Journal Articles

Mirna EXPRESSION SIGNATURES as PROGNOSTIC Markers IN ADVANCED Classical HODGKIN LYMPHOMA

Beatriz Sanchez-Espiridion, Carlos Montalban ESQ, MD, PhD, Pablo Guisado, Maria E. Rodriguez, Miguel Canales, Javier Alves, Francisco Vega, MD, PhD, Manuel Morente, José Francisco Tomás, Miguel A. Piris, Juan F. Garcia

Blood (2010) 116 (21): 4157.

https://doi.org/10.1182/blood.V116.21.4157.4157

Published: 2010

Journal Articles

Tailored Low Dose Lenalidomide with Low Dose Dexamethasone (len/dex) in Previously Treated Patients with Multiple Myeloma Older Than 70 Years Requiring Treatment.

Angel Ruedas, MD, Ricardo Perez, MD, Valentin Garcia, MD, Alicia Smucler, MD, Pilar Bravo, MD, Joaquin Martinez, MD, Pilar Sabin, MD, Pablo Guisado, MD, PhD, Carlos Montalban, PHD

Blood (2009) 114 (22): 4950.

https://doi.org/10.1182/blood.V114.22.4950.4950

Published: 2009

NARROW

The Pretreatment Absolute Lymphocyte Count (ALC), but Not the Absolute Monocyte Count (AMC) or ALC/AMC Ratio, Is an Independent Prognostic Factor in Aggressive Non-Hodgkin Lymphoma (aNHL)

Personalized Treatment with low doses of Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma in frail or Elderly Patients

Stratification Approach for Splenic Marginal Zone Lymphoma Based on Hemoglobin, Platelet Count, High LDH and Extrahilar Lymphadenopathy: The HPLL/ABC System

Mirna EXPRESSION SIGNATURES as PROGNOSTIC Markers IN ADVANCED Classical HODGKIN LYMPHOMA

Tailored Low Dose Lenalidomide with Low Dose Dexamethasone (len/dex) in Previously Treated Patients with Multiple Myeloma Older Than 70 Years Requiring Treatment.

Email alerts

ASH Publications

American Society of Hematology

The Pretreatment Absolute Lymphocyte Count (ALC), but Not the Absolute Monocyte Count (AMC) or ALC/AMC Ratio, Is an Independent Prognostic Factor in Aggressive Non-Hodgkin Lymphoma (aNHL)

Personalized Treatment with low doses of Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma in frail or Elderly Patients

Stratification Approach for Splenic Marginal Zone Lymphoma Based on Hemoglobin, Platelet Count, High LDH and Extrahilar Lymphadenopathy: The HPLL/ABC System

Mirna EXPRESSION SIGNATURES as PROGNOSTIC Markers IN ADVANCED Classical HODGKIN LYMPHOMA

Tailored Low Dose Lenalidomide with Low Dose Dexamethasone (len/dex) in Previously Treated Patients with Multiple Myeloma Older Than 70 Years Requiring Treatment.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only